ATLANTA, Ga., April 9, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting at the inaugural Atlanta Clinical Cardiology Update (CCU), presented by the Division of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory University, April 13-14, 2012. The inaugural meeting will provide a new, needs-based and convenient forum for knowledge exchange between general and sub-specialist cardiologists across the spectrum of cardiovascular disease.
FirstMark will showcase its new cardiovascular test PREvent at the meeting. PREvent is the first and only multiple biomarker blood test on the market that predicts near term (2-3 years) risk of myocardial infarction in patients with suspected or confirmed, insignificant or significant stable CAD. The test is an exciting development in cardiovascular medicine, providing a simple solution for the huge unmet need of assessing CAD patients risk of near term myocardial infarction.
"One of the goals of the inaugural Atlanta CCU meeting is to give attendees the opportunity to catch up on recent clinical trials that are likely to influence practice, presented at conferences such as the American Heart Association and American College of Cardiology Scientific Sessions. The clinical trial for PREvent, was conducted at Emory University and presented at both of these conferences in oral Poster Presentations," said Thomas Silberg, President and CEO of GenWay Biotech. "The final data is quite remarkable, and we are excited for the opportunity to once again highlight the study and present the test."
PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with al
|SOURCE GenWay Biotech|
Copyright©2010 PR Newswire.
All rights reserved